Penumbra has shown significant operating leverage and profitability, with strong topline growth. Find out my recommendation ...

BTIG analyst Ryan Zimmerman maintained a Buy rating on Penumbra (PEN – Research Report) yesterday and set a price target of $270.00. The ...

Robust improvement of Penumbra, Inc.’s PEN Thrombectomy business is poised to help the company grow in the upcoming quarters.

After the MedTech giant Stryker (NYSE:SYK) agreed to offer $4.9B in cash to acquire Inari Medical (NASDAQ:NARI), a maker of ...

Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians.

Penumbra is demonstrating strong growth within the company’s Thrombectomy business, banking on the rapid increase in sales of the company’s vascular thrombectomy products in the United States ...

In a report released on January 6, Shagun Singh Chadha from RBC Capital maintained a Buy rating on Penumbra (PEN – Research Report), with a ...

Director Harpreet Grewal sold 167 shares of the company’s stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $241.28, for a total value of $40,293.76. Following ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.